Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Head & Neck 1: Afatinib vs Methotrexate in R/M HNSCC
NCT01345682Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Boehringer Ingelheim. Started Jan 2012; status: completed.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01345682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01345682.